COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00731692




Registration number
NCT00731692
Ethics application status
Date submitted
7/08/2008
Date registered
11/08/2008
Date last updated
14/06/2017

Titles & IDs
Public title
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
Scientific title
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Secondary ID [1] 0 0
2007-002627-32
Secondary ID [2] 0 0
CFTY720D2306
Universal Trial Number (UTN)
Trial acronym
INFORMS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Progressive Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - FTY720
Treatment: Drugs - Placebo

Experimental: FTY720D 0.5 mg - Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment

Placebo Comparator: Placebo - Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization

Experimental: FTY720D 1.25 mg switch to 0.5 mg - Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009


Treatment: Drugs: FTY720
Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

Treatment: Drugs: Placebo
Matching placebo capsules were administered orally once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint - 3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.
Timepoint [1] 0 0
up to 36 months after the last patient was randomized
Secondary outcome [1] 0 0
Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS) - The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)
Timepoint [1] 0 0
up to 36 months after the last patient was randomized
Secondary outcome [2] 0 0
Percent Change From Baseline in Brain Volume at Month 36 - The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.
Timepoint [2] 0 0
Baseline to month 36
Secondary outcome [3] 0 0
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT. - The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
Timepoint [3] 0 0
up to 36 months after the last patient was randomized
Secondary outcome [4] 0 0
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT. - The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
Timepoint [4] 0 0
up to 36 months after the last patient was randomized
Secondary outcome [5] 0 0
Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36 - Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
Timepoint [5] 0 0
Baseline to 36 months
Secondary outcome [6] 0 0
Number of Gd-enhancing Lesions at Month 36 - Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
Timepoint [6] 0 0
Baseline to 36 months
Secondary outcome [7] 0 0
Percent Change in Total T2 Lesion Volume From Baseline to Month 36 - Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis
Timepoint [7] 0 0
Baseline to month 36
Secondary outcome [8] 0 0
Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score) - The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score
Timepoint [8] 0 0
Baseline, 36 months
Secondary outcome [9] 0 0
Change From Baseline in PRIMUS-Activities - The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).
Timepoint [9] 0 0
Baseline, 36 months
Secondary outcome [10] 0 0
Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score - Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).
Timepoint [10] 0 0
Baseline, 36 months
Secondary outcome [11] 0 0
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score) - EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Timepoint [11] 0 0
Baseline, 36 months
Secondary outcome [12] 0 0
Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score) - The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42*100).
Timepoint [12] 0 0
Baseline, 36 months
Secondary outcome [13] 0 0
Blood Concentrations of Fingolimod and Fingolimod-phosphate - Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate.
Venous blood samples were collected for the analysis.
Timepoint [13] 0 0
Month 3 up to 36 months
Secondary outcome [14] 0 0
Change in MSFC Z-score and Subscale Scores From Baseline to Month 36 - The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.
Timepoint [14] 0 0
Baseline to Month 36

Eligibility
Key inclusion criteria
General

1. sign written informed consent prior to participating in the study

2. 25 through 65 years of age inclusive

3. females of childbearing potential must:

- have a negative pregnancy test at Baseline (prior to randomization) and

- use simultaneously two forms of effective contraception during the treatment and
3-months after discontinuation of study medication

Primary Progressive Multiple sclerosis.

1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised
McDonald criteria):

2. time since first reported symptoms between 2 and 10 years

3. evidence of clinical disability progression in the 2 years prior to Screening

4. disability status at Screening

- EDSS score of 3.5-6.0 inclusive

- pyramidal functional system score of 2 or more

- 25'TWT less than 30 seconds

Extension study Inclusion criteria

- Patients initially randomized to fingolimod 1.25 mg or placebo as part of the first
study cohort, were to have completed at least 3 years on study drug treatment at the
time of extension study initiation.

- Patients initially randomized to fingolimod 0.5 mg or placebo as part of the second
study cohort, were to have continued on study drug treatment until such time as the
last ongoing patient enrolled in the study had reached 3 years in study
Minimum age
25 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
PPMS specific:

- History of relapses/attacks

- Progressive neurological disorder other than PPMS

- Pure cerebellar syndrome or pure visual progressive syndrome or pure

- cognitive progressive syndrome

- Presence of spinal cord compression at screening MRI

- Relevant history of vitamin B12 deficit

- Evidence of syphilis or borreliosis at Screening

Cardiovascular conditions:

- Myocardial infarction within the past 6 months or current unstable ischemic heart
disease

- History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon

- Severe cardiac failure or cardiac arrest

- History of symptomatic bradycardia

- Resting pulse <55 bpm pre-dose

- History of sick sinus syndrome or sino-atrial heart block

- History or presence of second and third degree AV block or an increase QT interval
(QTc>440 ms)

- Arrythmia requiring treatment with class III antiarrythmic drugs

- History of positive tilt test from workout of vasovagal syncope

- Hypertension, not controlled with medication

Pulmonary:

- Severe respiratory disease or pulmonary fibrosis

- TB

- Abnormal X-ray, suggestive of active pulmonary disease

- Abnormal PFT: <70% of predicted for FEV1 and FVC; <60% for DLCO

- Patients receiving chronic (daily) therapies for asthma

Hepatic:

- Known history of alcohol abuse, chronic liver or biliary disease

- Total or conjugated Brb >ULN, unless in context of Gilbert's syndrome

- AP >1.5xULN; ALT/AST >2xULN; GGT>3xULN

Other:

- History of chronic disease of the immune system other than MS

- Malignancy (other than successfully treated SCC or BCC)

- Diabetes Mellitus

- Macular Edema present at screening

- HIV, Hepatitis C or B, other active infection

- History of total lymphoid irradiation or bone marrow transplantation

- Serum creatinine >1.7 mg/dl

- WBC <3500 cells/mm3

- Lymphocyte count <800 cells/mm3

- History of substance abuse or any other factor that may interfere with subject ability
to cooperate and comply with the study procedures

- Unable to undergo MRI scans

- Participation in any therapeutical clinical research study in the 6 months prior to
randomization

- Pregnant or lactating women

- Drugs requiring wash-out period:

3 months:

- Systemic corticosteroids or ACTH

- INF-beta

6 months:

- Immunosuppressive medication

- Immunoglobulins

- Monoclonal antibodies

- Drugs that exclude participation in the study:

- Cladribine

- Cyclophosphamide

- Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2
more than 5 years ago could enter the study)

Extension study Exclusion criteria

-Patients were not eligible for enrollment in the extension study if they had any of the
following key exclusion criteria at the extension study Baseline visit: active chronic
immune system disease other than MS (or stable disease treated with immune therapy); known
immunodeficiency syndrome; active infection; uncontrolled diabetes mellitus; macularedema;
treatment with Class Ia or III antiarrhythmic drugs; any of the specified cardiac,
pulmonary, or hepatic conditions; or any medically unstable condition

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Camperdown
Recruitment hospital [2] 0 0
Novartis Investigative Site - Liverpool
Recruitment hospital [3] 0 0
Novartis Investigative Site - Hobart
Recruitment hospital [4] 0 0
Novartis Investigative Site - Box Hill
Recruitment hospital [5] 0 0
Novartis Investigative Site - Heidelberg
Recruitment hospital [6] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
7000 - Hobart
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Vermont
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Belgium
State/province [22] 0 0
Charleroi
Country [23] 0 0
Belgium
State/province [23] 0 0
Edegem
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Belgium
State/province [25] 0 0
Liege
Country [26] 0 0
Belgium
State/province [26] 0 0
Melsbroek
Country [27] 0 0
Belgium
State/province [27] 0 0
Sint-Truiden
Country [28] 0 0
Canada
State/province [28] 0 0
Alberta
Country [29] 0 0
Canada
State/province [29] 0 0
British Columbia
Country [30] 0 0
Canada
State/province [30] 0 0
Nova Scotia
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Canada
State/province [33] 0 0
Saskatchewan
Country [34] 0 0
Czechia
State/province [34] 0 0
Czech Republic
Country [35] 0 0
Czechia
State/province [35] 0 0
CZE
Country [36] 0 0
Czechia
State/province [36] 0 0
Ostrava-Poruba
Country [37] 0 0
Czechia
State/province [37] 0 0
Plzen
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 2
Country [39] 0 0
Czechia
State/province [39] 0 0
Teplice
Country [40] 0 0
Denmark
State/province [40] 0 0
Aarhus
Country [41] 0 0
Denmark
State/province [41] 0 0
Sønderborg
Country [42] 0 0
Finland
State/province [42] 0 0
Helsinki
Country [43] 0 0
Finland
State/province [43] 0 0
Tampere
Country [44] 0 0
Finland
State/province [44] 0 0
Turku
Country [45] 0 0
France
State/province [45] 0 0
Bordeaux Cedex
Country [46] 0 0
France
State/province [46] 0 0
Lille Cedex
Country [47] 0 0
France
State/province [47] 0 0
Marseille cedex 05
Country [48] 0 0
France
State/province [48] 0 0
Montpellier
Country [49] 0 0
France
State/province [49] 0 0
Nantes Cedex 1
Country [50] 0 0
France
State/province [50] 0 0
Paris Cedex 13
Country [51] 0 0
France
State/province [51] 0 0
Rennes
Country [52] 0 0
France
State/province [52] 0 0
Strasbourg
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Bochum
Country [55] 0 0
Germany
State/province [55] 0 0
Dresden
Country [56] 0 0
Germany
State/province [56] 0 0
Duesseldorf
Country [57] 0 0
Germany
State/province [57] 0 0
Erlangen
Country [58] 0 0
Germany
State/province [58] 0 0
Essen
Country [59] 0 0
Germany
State/province [59] 0 0
Freiburg
Country [60] 0 0
Germany
State/province [60] 0 0
Hannover
Country [61] 0 0
Germany
State/province [61] 0 0
Hennigsdorf
Country [62] 0 0
Germany
State/province [62] 0 0
Magdeburg
Country [63] 0 0
Germany
State/province [63] 0 0
Muenchen
Country [64] 0 0
Germany
State/province [64] 0 0
Muenster
Country [65] 0 0
Germany
State/province [65] 0 0
Munchen
Country [66] 0 0
Germany
State/province [66] 0 0
Teupitz
Country [67] 0 0
Germany
State/province [67] 0 0
Trier
Country [68] 0 0
Germany
State/province [68] 0 0
Würzburg
Country [69] 0 0
Hungary
State/province [69] 0 0
Budapest
Country [70] 0 0
Hungary
State/province [70] 0 0
Debrecen
Country [71] 0 0
Hungary
State/province [71] 0 0
Gyor
Country [72] 0 0
Hungary
State/province [72] 0 0
Miskolc
Country [73] 0 0
Hungary
State/province [73] 0 0
Veszprem
Country [74] 0 0
Italy
State/province [74] 0 0
BA
Country [75] 0 0
Italy
State/province [75] 0 0
BS
Country [76] 0 0
Italy
State/province [76] 0 0
CH
Country [77] 0 0
Italy
State/province [77] 0 0
CT
Country [78] 0 0
Italy
State/province [78] 0 0
GE
Country [79] 0 0
Italy
State/province [79] 0 0
MI
Country [80] 0 0
Italy
State/province [80] 0 0
PA
Country [81] 0 0
Italy
State/province [81] 0 0
PD
Country [82] 0 0
Italy
State/province [82] 0 0
RM
Country [83] 0 0
Italy
State/province [83] 0 0
TO
Country [84] 0 0
Italy
State/province [84] 0 0
VA
Country [85] 0 0
Netherlands
State/province [85] 0 0
CK
Country [86] 0 0
Netherlands
State/province [86] 0 0
Amsterdam
Country [87] 0 0
Netherlands
State/province [87] 0 0
Eindhoven
Country [88] 0 0
Netherlands
State/province [88] 0 0
Nieuwegein
Country [89] 0 0
Netherlands
State/province [89] 0 0
Nijmegen
Country [90] 0 0
Netherlands
State/province [90] 0 0
Sittard-Geleen
Country [91] 0 0
Poland
State/province [91] 0 0
Lodz
Country [92] 0 0
Poland
State/province [92] 0 0
Lublin
Country [93] 0 0
Poland
State/province [93] 0 0
Warszawa
Country [94] 0 0
Spain
State/province [94] 0 0
Andalucia
Country [95] 0 0
Spain
State/province [95] 0 0
Catalunya
Country [96] 0 0
Spain
State/province [96] 0 0
Comunidad Valenciana
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid
Country [98] 0 0
Spain
State/province [98] 0 0
Pais Vasco
Country [99] 0 0
Sweden
State/province [99] 0 0
Goeteborg
Country [100] 0 0
Sweden
State/province [100] 0 0
Stockholm
Country [101] 0 0
Switzerland
State/province [101] 0 0
Basel
Country [102] 0 0
Switzerland
State/province [102] 0 0
Bern
Country [103] 0 0
Switzerland
State/province [103] 0 0
Lausanne
Country [104] 0 0
Switzerland
State/province [104] 0 0
Lugano
Country [105] 0 0
Switzerland
State/province [105] 0 0
Zuerich
Country [106] 0 0
Turkey
State/province [106] 0 0
Ankara
Country [107] 0 0
Turkey
State/province [107] 0 0
Atakum / Samsun
Country [108] 0 0
Turkey
State/province [108] 0 0
Balcova / Izmir
Country [109] 0 0
Turkey
State/province [109] 0 0
Istanbul
Country [110] 0 0
Turkey
State/province [110] 0 0
Yenisehir / Izmir
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Manchester
Country [112] 0 0
United Kingdom
State/province [112] 0 0
South Yorkshire
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Bristol
Country [114] 0 0
United Kingdom
State/province [114] 0 0
London
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Newcastle Upon Tyne
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Norwich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS
disability progression compared to placebo in patients with PPMS. This was an open-label,
single-arm extension study to a double-blind, randomized multicenter, placebo-controlled,
parallel-group core study. The core study completed and eligible patients enrolled into the
extension study at the next scheduled or unscheduled core study visit. All patients,
regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension
study. The extension study was terminated early after the results of the core study became
available showing that the study did not meet its primary endpoint which was defined as
confirmed disability progression in this population
Trial website
https://clinicaltrials.gov/show/NCT00731692
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT00731692